VDHG

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

ETHI

ETHI.AX was created on 2017-01-05 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes a portfolio of large global stocks identified as Climate Leaders that have also passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.

A200

A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 2975.21m in AUM and 200 holdings. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.

Cochlear Limited

COH

Cochlear Ltd. engages in the provision of implantable hearing solutions. The company is headquartered in Sydney, New South Wales and currently employs 4,500 full-time employees. The firm designs and offers products and accessories for adults or children. The firm operates through three segments: Cochlear implants, Services and Acoustics. The Company’s Cochlear implants segment offers Cochlear implant systems, including Cochlear Nucleus Profile Plus with Slim Modiolar Electrode (CI632). Its Services segment offers sound processor upgrades, accessories and other, including Cochlear Nucleus 7 Sound Processor and Cochlear Nucleus Kanso 2 Sound Processor. Its Acoustics segment offers Bone Conduction systems and Sound processor upgrades, including Cochlear Osia 2 System and Cochlear Baha 6 Max Sound Processor. Its products and accessories include Cochlear Nucleus System, Cochlear Baha System and Cochlear Baha Start. The firm operates in America; Europe, the Middle East and Africa (EMEA), and Asia Pacific.

CSL Limited

CSL

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. The company is headquartered in Melbourne, Victoria and currently employs 30,000 full-time employees. The Company’s areas of focus and exploration include rare and serious diseases, influenza vaccines, plasma collection, and therapies for iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment manufactures, markets, and distributes plasma therapies (plasma products and recombinants). CSL Seqirus segment manufactures, markets, and distributes primarily influenza-related products and provides pandemic services to governments. The Company’s CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency, dialysis and nephrology and rare diseases. The Company’s geographical areas of operation include Australia, the United States of America, Germany, the United Kingdom, Switzerland, and China. CSL’s products include HIZENTRA, PRIVIGEN, IDELVION, HAEMATE, KCENTRA, HAEGARDA, ZEMAIRA/RESPREEZA, FLUAD and FLUCELVAX.